Abstract: Systems and methods for ingesting and enhancing data in a distributed processing framework. The system includes at least a data ingestion system configured to access data or datasets from one or more data sources. The data is accessed via the data ingestion system and includes metadata defining a plurality of attributes. The attributes are identified in the metadata, via the data ingestion system, and may be applied to the data or dataset for enhancing the data or dataset. Application of the attributes to the data results in enhancements that may include joining the data, enriching the data, or other enhancements accomplished via manipulation of the data via the data ingestion system.

Abstract: Systems and methods for populating data in a client specific repository in a public cloud infrastructure is described. The system includes a private master data repository (MDR) implemented in a private network and having data stored therein. A client submits a data request to access the MDR and to perform an operation on data within the MDR. The data request may include information for identifying the client and information for determining whether the client is authorized to perform the requested operation. The system further includes a persistence mechanism configured to interface with the MDR in response to the data request. Upon verifying the client is authorized to access the MDR, the persistence mechanism may be configured to provision a directory in the public cloud infrastructure and to create and populate data in the client specific repository as a persistent state of the data in the MDR.

Abstract: Systems and methods for populating data in a client specific repository in a public cloud infrastructure is described. The system includes a private master data repository (MDR) implemented in a private network and having data stored therein. A client submits a data request to access the MDR and to perform an operation on data within the MDR. The data request may include information for identifying the client and information for determining whether the client is authorized to perform the requested operation. The system further includes a persistence mechanism configured to interface with the MDR in response to the data request. Upon verifying the client is authorized to access the MDR, the persistence mechanism may be configured to provision a directory in the public cloud infrastructure and to create and populate data in the client specific repository as a persistent state of the data in the MDR.

Abstract: Systems and methods for ingesting and enhancing data in a distributed processing framework. The system includes at least a data ingestion system configured to access data or datasets from one or more data sources. The data is accessed via the data ingestion system and includes metadata defining a plurality of attributes. The attributes are identified in the metadata, via the data ingestion system, and may be applied to the data or dataset for enhancing the data or dataset. Application of the attributes to the data results in enhancements that may include joining the data, enriching the data, or other enhancements accomplished via manipulation of the data via the data ingestion system.

Abstract: Disclosed is an implantable device with enhanced drug delivery area, wherein a pre-crimped stent assembly mounted on a balloon further comprises a homogenous coating of drug and associated polymeric matrix resulting in the formation of a circumferential cylindrical film formation, upon expansion of the balloon. The cylindrical film formation by the drug delivery medical devices enables maximum coverage area of the vascular lumen area, thereby preventing any untreated area within a lumen.

Abstract: A system for preventing a distributed denial of service (DDoS) attack is disclosed. The system includes a content delivery network (CDN) server connected to Internet, a server connected to the Internet, and a token generator connected to the Internet. The CDN server, the server and the token generator are configured to perform an operation. The operation includes rendering a static login page on a remote computer, receiving entered login information at a token generator through User Datagram Protocol (UDP) from the remote computer, authenticating the received login information by the token generator using an authentication module that is aware of authentication requirements of the server, sending a token and a cookie back to the remote computer, receiving, at the server, a SYN packet with the token from the remote computer, verifying the received token by the web server, and sending an ACK packet back to the remote server from the web server.

Abstract: An implantable biodegradable device having two or more layers composed of one or more biodegradable materials is disclosed. The two or more layers are coated with one or more drugs. The implantable biodegradable device further having one or more inert layers is composed of a biodegradable material. The one or more inert layers of the implantable biodegradable device are degraded in response to introduction of one or more external triggers when the implantable biodegradable medical device is placed within a living organism. Further, a layer of the two or more layers having a position above an inert layer is degraded prior to degradation of the inert layer. Subsequently, a layer of the two or more layers having a position below the inert layer is degraded subsequent to degradation of the inert layer.

Abstract: An implantable biodegradable device having two or more layers composed of one or more biodegradable materials is disclosed. The two or more layers are coated with one or more drugs. The implantable biodegradable device further having one or more inert layers is composed of a biodegradable material. The one or more inert layers of the implantable biodegradable device are degraded in response to introduction of one or more external triggers when the implantable biodegradable medical device is placed within a living organism. Further, a layer of the two or more layers having a position above an inert layer is degraded prior to degradation of the inert layer. Subsequently, a layer of the two or more layers having a position below the inert layer is degraded subsequent to degradation of the inert layer.

Abstract: A drug-delivering insertable medical device for treating a medical condition associated with a body lumen is disclosed. The drug-delivering insertable medical device includes an outer surface coated with two or more nano-carriers having two or more average diameters. A nano-carrier of the two or more nano-carriers has an average diameter suitable for penetrating one or more layers of two or more layers of the body lumen. The nano-carrier includes a drug surrounded by an encapsulating medium. The encapsulating medium includes one or more of a biological agent, a blood excipient, and a phospholipid.

Abstract: A balloon catheter assembly for delivering nano-carriers to bifurcation lesions in one or more of a main branch and a side branch of a blood vessel bifurcation within 30 to 90 seconds is provided. The balloon catheter assembly includes two or more balloons designed for use in the blood vessel bifurcation. The balloon catheter assembly may also include one or more stents. A surface of one or more of the two or more balloons is coated with the nano-carriers. Stents, when included, may also be coated with the nano-carriers. The nano-carriers include one or more drugs encapsulated with one or more biological agents.

Abstract: The invention discloses an insertable medical device for delivering one or more pro-healing agents to a site of deployment of a stent in a blood vessel. The surface of the insertable medical device is coated with nano-carriers that include the one or more pro-healing agents encapsulated with one or more biological agents. The nano-carriers are released when the insertable medical device is expanded at the site. The nano-carriers thus released penetrate tissues at the site resulting in dissolution of the one or more biological agents. Thereafter, the one or more pro-healing agents are released from the nano-carriers at the site. Thus, an in-tissue release of the one or more pro-healing agents at the site is achieved thereby improving endothealization, extracellular matrix formation and healing at the site post deployment of the stent in the blood vessel.

Abstract: A drug-delivering medical device for treating a medical condition associated with a body lumen is provided. The drug-delivering medical device includes an outer abluminal aspect having a micro-porous surface embedded with nano-carriers having an assortment of average diameters. The nano-carriers penetrate one or more layers of a wall of the body lumen. The micro-porous surface and the nano-carriers enable the device to release a drug for up to 60 days.

Abstract: A method for delivering at least one drug at a target site in a blood vessel for treating at least one of an acute myocardial infarction, a thrombus containing lesion and a saphenous-vein graft lesion is disclosed. The method includes delivering nano-carriers at the target site. The nano-carriers include one or more drugs encapsulated with a first biological agent. The nano-carriers further include a second biological agent in contact with one or more of the first biological agent and the one or more drugs. The first biological agent and the second biological agent have a first dissolution rate and a second dissolution rate respectively. The first dissolution rate is different from the second dissolution rate. The one or more drugs are released at the target site from the nano-carriers at a first release rate and a second release rate in response to dissolution of the first biological agent and the second biological agent, respectively.

Abstract: A drug-delivering insertable medical device for treating a medical condition associated with a body lumen is disclosed. The drug-delivering insertable medical device includes an outer surface coated with two or more nano-carriers having two or more average diameters. A nano-carrier of the two or more nano-carriers has an average diameter suitable for penetrating one or more layers of two or more layers of the body lumen. The nano-carrier includes a drug surrounded by an encapsulating medium. The encapsulating medium includes one or more of a biological agent, a blood excipient, and a phospholipid.

Abstract: A drug-delivering medical device for delivering a drug to a target site in a human body is disclosed. The drug-delivering medical device may have a hydrophilic surface, with one or more portions of the hydrophilic surface coated with one or more nano-carriers bearing one or more drugs. Each nano-carrier may include a drug surrounded by an encapsulating medium. As the drug is surrounded by the encapsulating medium, the surface of each nano-carrier can be devoid of the respective drug. A non-implantable medical device coated with nano-carriers can deliver one or more drugs to a blood vessel, organ cavity, sac, capsule, lining, layer, coating, membrane, connective tissue, fluid surrounding an organ, and so forth.

Abstract: A drug-delivering medical device for delivering a drug to a target site in a body lumen is disclosed. The drug-delivering medical device includes a balloon catheter and an inflatable balloon positioned on the balloon catheter. The inflatable balloon has a hydrophilic surface. One or more portions of the hydrophilic surface are coated with two or more nano-carriers. A nano-carrier of the two or more nano-carriers includes a drug surrounded by an encapsulating medium. As the drug is surrounded by the encapsulating medium, the surface of the nano-carrier is devoid of the drug. When the inflatable balloon is inflated upon coming in proximity to a target site in the body lumen, about 30% to 80% of the two or more nano-carriers are released from the hydrophilic surface within 15-90 seconds.

Abstract: The invention discloses a method of coating a medical device. The method includes applying a coating composition on the medical device to form a layer on the medical device. The coating composition includes one or more of one or more biological agents and heparin dissolved in a mixture of a first solvent and a second solvent. The first solvent and the second solvent have different evaporation temperatures. Subsequently, at least a part of one of the first solvent and the second solvent present in the coating composition is evaporated to create a plurality of pores in the layer. Thereafter, one or more drugs are deposited in the plurality of pores. When the medical device is positioned and expanded at a target site, the one or more drugs are released from the plurality of pores.

Abstract: A drug-delivering insertable medical device for treating a medical condition associated with a body lumen is disclosed. The drug-delivering insertable medical device includes an outer surface coated with two or more nano-carriers having two or more average diameters. A nano-carrier of the two or more nano-carriers has an average diameter suitable for penetrating one or more layers of two or more layers of the body lumen. The nano-carrier includes a drug surrounded by an encapsulating medium. The encapsulating medium includes one or more of a biological agent, a blood excipient, and a phospholipid.

Abstract: A balloon catheter assembly for delivering nano-carriers to bifurcation lesions in one or more of a main branch and a side branch of a blood vessel bifurcation within 30 to 90 seconds is provided. The balloon catheter assembly includes two or more balloons designed for use in the blood vessel bifurcation. The balloon catheter assembly may also include one or more stents. A surface of one or more of the two or more balloons is coated with the nano-carriers. Stents, when included, may also be coated with the nano-carriers. The nano-carriers include one or more drugs encapsulated with one or more biological agents.

Abstract: An implantable biodegradable device having two or more layers composed of one or more biodegradable materials is disclosed. The two or more layers are coated with one or more drugs. The implantable biodegradable device further having one or more inert layers is composed of a biodegradable material. The one or more inert layers of the implantable biodegradable device are degraded in response to introduction of one or more external triggers when the implantable biodegradable medical device is placed within a living organism. Further, a layer of the two or more layers having a position above an inert layer is degraded prior to degradation of the inert layer. Subsequently, a layer of the two or more layers having a position below the inert layer is degraded subsequent to degradation of the inert layer.